Clinical trials: Epithelial Mesothelioma
Medical Oncology
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Determine the safety, tolerability and maximum tolerated dose of anetumab ravtansine (BAY 94-9343) in combination with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 in subjects with mesothelin-expressing predominantly epithelial…
- Trial name
- NCT02639091
- Testing
- BAY 94-9343, Pemetrexed, Cisplatin
- Where
- 6 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Bayer
Malignant Pleural Mesothelioma, Nonsquamous Nonsmall Cell Neoplasm of Lung
Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin
This is a prospective, open-label, mono-centric, phase I-Ib trial of Tivantinib in combination with Pemetrexed and Carboplatin as first-line therapy in patients with advanced or metastatic cancer suitable for a Carboplatin and…
- Trial name
- NCT02049060
- Testing
- Tivantinib
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- Armando Santoro, MD
Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant pleural mesothelioma.
- Conditions
- Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma
- Trial name
- NCT00459862
- Testing
- laboratory biomarker analysis, pazopanib hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Mesothelioma
Autologous Redirected RNA Meso-CIR T Cells
To determine the safety and manufacturing feasibility of IV autologous chimeric immune receptor (CIR) T cells transfected with anti-mesothelin messenger RNA (mRNA) expressing a single chain antibody variable fragment linked to…
- Trial name
- NCT01355965
- Testing
- Autologous T cells
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Pennsylvania
Mesothelioma, Small Cell Lung Cancer, NSCLC
Validation of the MiCK Assay
Testing Mayo Clinic cancer patients with the results being correlated with prior patient therapy, performance status, and extent of disease.
- Trial name
- MiCK Assay (NCT01770665)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Pierian Biosciences
Peritoneal Carcinomatosis, Colorectal Cancer
HIPEC for Peritoneal Carcinomatosis
This is a clinical study investigating the new treatment of surgery combined with intraperitoneal mitomycin-C for patients with gastrointestinal cancer that has spread to the peritoneal (abdominal cavity) surface.
- Conditions
- Peritoneal Carcinomatosis, Colorectal Cancer, Appendiceal Cancer, Peritoneal Mesothelioma
- Trial name
- NCT02040142
- Testing
- HIPEC, Mitomycin C
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Albert Einstein College of Medicine
Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer)
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are…
- Conditions
- Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
- Trial name
- NCT05873686
- Testing
- NXP900
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Nuvectis Pharma, Inc.
Lung Cancer, Gastro-Intestinal Cancer
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program
This study evaluates physical performance in cancer outpatients during a multimodal therapy. Half of the patients will receive physical exercise und nutrition program in combination with a specially formulated whey protein…
- Conditions
- Lung Cancer, Gastro-Intestinal Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT02585362
- Testing
- physical exercise, nutrition counseling, whey protein supplement
- Where
- Switzerland
- Volunteers
- 52 people
- Sponsor
- Kantonsspital Winterthur KSW
Soft Tissue Sarcoma, Mesothelioma
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
The purpose of this study is to determine safety and toxicity for the combination of Temozolomide and Azacitidine in the treatment of Advanced Soft Tissue Sarcoma or Malignant Mesothelioma.
- Trial name
- NCT00629343
- Testing
- Azacitidine, Temozolomide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Columbia University
Pleural Carcinomatosis
Probe Based Confocal Laser Endomicroscopy During Thoracoscopy for Pleural Malignancies Diagnosis.
Probe based confocal laser endomicroscopy (pCLE) is a new optical endoscopic technique, generating fluorescent light emission from the tissue of interest and allowing in vivo live imaging at a cellular level ("optical biopsies").
- Trial name
- NCT03805971
- Testing
- Study of the pleural cavity with a confocal laser endomicroscope.
- Where
- Belgium
- Volunteers
- 65 people
- Sponsor
- University of Liege
Mesothelioma
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
A clinical study to assess if a new investigational drug is effective in treating malignant mesothelioma, compared to a chemotherapy treatment (Navelbine®).
- Trial name
- NCT00597116
- Testing
- Vinorelbine, Vandetanib
- Where
- 6 sites in Germany, Switzerland
- Volunteers
- 25 people
- Sponsor
- Genzyme, a Sanofi Company
Mesothelioma, Malignant
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
This study was originally designed as a multicenter, double-blind, randomized, parallel-group study, using a placebo control or amatuximab 5 milligrams per kilogram (mg/kg), administered weekly, designed to evaluate the safety…
- Trial name
- ARTEMIS (NCT02357147)
- Testing
- Amatuximab, Pemetrexed, Cisplatin
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 124 people
- Sponsor
- Morphotek
Cancer
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
RATIONALE: Using BG00001 to insert the gene for interferon-beta into a person's pleural cavity may improve the body's ability to fight cancer.
- Trial name
- NCT00066404
- Testing
- recombinant adenovirus-hIFN-beta
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non Small Cell Lung Cancer, Mesothelioma
Dose Individualization of Pemetrexed - IMPROVE-I
Rationale: Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma.
- Trial name
- IMPROVE-I (NCT03656549)
- Testing
- Pemetrexed + oral folinic acid rescue
- Where
- 6 sites in Netherlands
- Volunteers
- 6 people
- Sponsor
- Radboud University Medical Center
Malignant Mesothelioma
Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00253409
- Testing
- chemotherapy, adjuvant therapy, conventional surgery
- Where
- 17 sites in United Kingdom
- Volunteers
- 670 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Mesothelioma
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Objectives: The investigators will test whether combination of chemoimmunotherapy or dual agent immunotherapy alone improves efficacy for patients with MPM.
- Trial name
- NCT05932199
- Testing
- Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Metastatic Cancer, Solid Tumor
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
- Trial name
- NCT04672434
- Testing
- Sym021, Sym024
- Where
- 4 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Symphogen A/S
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Bronchial Cancer, Malignant Mesothelioma
Rehabilitation by Effort for Patients With Advanced Bronchial Cancer
Bronchopulmonary cancers or mesothelioma are associated with effort deconditioning due to pathology (chronic inflammation) and also to treatments (surgery, radiotherapy, chemotherapy); it's considerably alters patients quality of…
- Trial name
- RehabKBP (NCT03684486)
- Testing
- rehabilitation by effort
- Where
- France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Toulouse
Mesothelioma
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab
- Trial name
- NCT00295503
- Testing
- bevacizumab, cisplatin, pemetrexed
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Texas Southwestern Medical Center